
Karine Charton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1158024/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Interactions with M-band Titin and Calpain 3 Link Myospryn (CMYA5) to Tibial and Limb-girdle Muscular Dystrophies. Journal of Biological Chemistry, 2010, 285, 30304-30315.	1.6	59
2	A new titinopathy. Neurology, 2015, 85, 2126-2135.	1.5	44
3	Restriction of Calpain3 Expression to the Skeletal Muscle Prevents Cardiac Toxicity and Corrects Pathology in a Murine Model of Limb-Girdle Muscular Dystrophy. Circulation, 2013, 128, 1094-1104.	1.6	40
4	Circulating miRNAs are generic and versatile therapeutic monitoring biomarkers in muscular dystrophies. Scientific Reports, 2016, 6, 28097.	1.6	38
5	A human skeletal muscle interactome centered on proteins involved in muscular dystrophies: LGMD interactome. Skeletal Muscle, 2013, 3, 3.	1.9	36
6	CAPN3-mediated processing of C-terminal titin replaced by pathological cleavage in titinopathy. Human Molecular Genetics, 2015, 24, 3718-3731.	1.4	36
7	A comparison of AAV strategies distinguishes overlapping vectors for efficient systemic delivery of the 6.2 kb Dysferlin coding sequence. Molecular Therapy - Methods and Clinical Development, 2015, 2, 15009.	1.8	36
8	AAV-mediated transfer of FKRP shows therapeutic efficacy in a murine model but requires control of gene expression. Human Molecular Genetics, 2017, 26, 1952-1965.	1.4	35
9	Removal of the calpain 3 protease reverses the myopathology in a mouse model for titinopathies. Human Molecular Genetics, 2010, 19, 4608-4624.	1.4	31
10	Cis -splicing and Translation of the Pre- Trans -splicing Molecule Combine With Efficiency in Spliceosome-mediated RNA Trans -splicing. Molecular Therapy, 2014, 22, 1176-1187.	3.7	29
11	RNA-targeting approaches for neuromuscular diseases. Trends in Molecular Medicine, 2009, 15, 580-591.	3.5	22
12	Exploiting the CRISPR/Cas9 system to study alternative splicingin vivo: application to titin. Human Molecular Genetics, 2016, 25, ddw280.	1.4	21
13	Diagnostic anoctaminâ€5 protein defect in patients with ANO5â€mutated muscular dystrophy. Neuropathology and Applied Neurobiology, 2018, 44, 441-448.	1.8	19
14	Titin splicing regulates cardiotoxicity associated with calpain 3 gene therapy for limb-girdle muscular dystrophy type 2A. Science Translational Medicine, 2019, 11, .	5.8	19
15	Endoplasmic reticulum maintains ion homeostasis required for plasma membrane repair. Journal of Cell Biology, 2021, 220, .	2.3	17
16	The Phenotype of Dysferlin-Deficient Mice Is Not Rescued by Adeno-Associated Virus–Mediated Transfer of Anoctamin 5. Human Gene Therapy Clinical Development, 2013, 24, 65-76.	3.2	15
17	Anoctamin 5 Knockout Mouse Model Recapitulates LGMD2L Muscle Pathology and Offers Insight Into in vivo Functional Deficits. Journal of Neuromuscular Diseases, 2021, 8, S243-S255.	1.1	5
18	377. AAV-Mediated Transfer of FKRP Shows Therapeutic Efficacy in a Murine Model of Limb-Girdle Muscular Dystrophy Type 2i, but Requires Tight Control of Gene Expression. Molecular Therapy, 2016, 24, S150.	3.7	0